Cancer‐stromal cell fusion as revealed by fluorescence protein tracking. Issue 3 (17th December 2019)

• Record Type: Journal Article
• Authors: Wang, Ruoxiang; Lewis, Michael S.; Lyu, Ji; Zhau, Haiyen E.; Pandol, Stephen J.; Chung, Leland W. K.
• Is Part Of: Prostate. Volume 80:Issue 3(2020)
• Page Start: 274
• Page End: 283
• Publication Date: 2019-12-17
• Subjects: cancer‐stromal interaction -- cell fusion -- fluorescence protein -- mesenchymal stromal cells -- prostate cancer -- tumor cell heterogeneity -- tumor microenvironment; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.23941
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract: Purpose: We previously determined that cancer‐stromal interaction was a direct route to tumor cell heterogeneity progression, since cancer‐stromal cell fusion in coculture resulted in the creation of heterogeneous clones of fusion hybrid progeny. In this report, we modified the cancer‐stromal coculture system to establish optimal experimental conditions for investigating cell fusion machinery and the mechanism of heterogeneity progression. Experimental design: Red fluorescence protein‐tagged LNCaP cells were cocultured with green fluorescence protein‐labeled prostate stromal cells for cancer‐stromal cell fusion, which was tracked as dual fluorescent cells by fluorescence microscopy. Results: We identified the most efficient strategy to isolate clones of fusion hybrid progenies. From the coculture, mixed cells including fusion hybrids were subjected to low‐density replating for colony formation by fusion hybrid progeny. These colonies could propagate into derivative cell populations. Compared to the parental LNCaP cells, clones of the fusion hybrid progeny displayed divergent behaviors and exhibited permanent genomic hybridization. Conclusions: Cancer‐stromal cell fusion leads to cancer cell heterogeneity. The cancer‐stromal coculture system characterized in this study can be used as a model for molecular characterization of cancer cell fusion as the mechanism behind the progression of heterogeneity observed in clinical prostate cancers.